For in vitro diagnostic use. Others FCAL IVD FCAL CPS_000141 fCAL turbo 08910367190 fCAL, 200T, cobas c pack green, PCh FCAL 04260714340007 Reagents, kits 200 tests cobas c 303/503 true 08910332190 fCAL, 200T, cobas c 501/502, PCh FCAL 07613336169926 Reagents, kits 200 tests cobas c 501/502 true 0108910367190c503 FCAL fCAL turbo en 2 FF00000005A8840E FF00000005A8840E 08910367190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe fCAL turbo is an automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens intended as an aid in the assessment of intestinal mucosal inflammationLREFNilsen T et al.: J Clin Lab Anal 2017 ; 31(4). doi: 10.1002/jcla.22061,LREFMandic-Havelka A et al.: Clin Lab. 2017 ; 63(5):907-913.,LREFNoebauer B et al. : Biochem Med (Zagreb) 2017 ; 27(3):030710.. The assay results can be used as an aid to diagnosis in distinguishing organic, inflammatory disease of the gastrointestinal tract (inflammatory bowel disease, IBD, specifically Crohn’s disease (CD) or ulcerative colitis (UC)) from functional disease (irritable bowel syndrome, IBS)LREFFagerhol MK: Lancet 2000; 356, 1783-4.,LREFTibble JA et al.: Gut 2000; 47, 506-13.,LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.,LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.,LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.,LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.,LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34., in patients with chronic abdominal pain and as an aid to IBD disease monitoringLREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.,LREFLin et al.: Inflamm Bowel Dis 2014; 20: 1407-15.,LREFLobatón T et al.: J Crohns Colitis 2013, 641-51.,LREFLobatón T et al.: Inflamm Bowel Dis 2013; 19(5), 1034-42.,LREFWright et al.: Gastroenterology 2015; 148(5), 938-947.,LREFNaismith GD et al.: J Crohns Colitis 2014; 8, 1022-9.,LREFFerreiro-Iglesias R et al.: Scand J Gastroenterol 2015, 23, 1-6.,LREFFerreiro-Iglesias R1 et al. : J Clin Gastroenterol 2015; 50(2),147-51.,LREFGuardiola J. et al. Clinical Gastroenterology & Hepatology 2014; 12(11) 1865-70.,LREFLasson A et al.: United European Gastroenterol J 2015, 3(1) 72-9.,LREFBressler B et al.: Can J Gastroenterol Hepatol 2015, 29(7), 369-72.,LREFPeyrin-BL et al.: Am J Gastroenterol 2015, 110, 1324-38.,LREFRicciuto A et al.: Crit Rev Clin Lab Sci. 2019; 56(5):307-320.. For laboratory use only. en 0208910367190c503 FCAL fCAL turbo en 2 FF00000005B1D20E FF000000057E340E 08910367190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings. en 0008910332190c501 FCAL fCAL turbo en 1 FF00000003CED60E FF00000003CED50E 08910332190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings. The fCAL turbo is intended to be run on cobas c 501/502 systems. en 0108910332190c501 FCAL fCAL turbo en 3 FF000000058C890E FF000000040D4A0E 08910332190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe fCAL turbo is an automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens intended as an aid in the assessment of intestinal mucosal inflammation.LREFNilsen T et al.: J Clin Lab Anal 2017 ; 31(4). doi: 10.1002/jcla.22061,LREFMandic-Havelka A et al.: Clin Lab. 2017 ; 63(5):907-913.,LREFNoebauer B et al. : Biochem Med (Zagreb) 2017 ; 27(3):030710. The assay results can be used as an aid to diagnosis in distinguishing organic, inflammatory disease of the gastrointestinal tract (inflammatory bowel disease, IBD, specifically Crohn’s disease (CD) or ulcerative colitis (UC)) from functional disease (irritable bowel syndrome, IBS),LREFFagerhol MK: Lancet 2000; 356, 1783-4.,LREFTibble JA et al.: Gut 2000; 47, 506-13.,LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.,LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.,LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.,LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.,LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34. in patients with chronic abdominal pain and as an aid to IBD disease monitoring.LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.,LREFLin et al.: Inflamm Bowel Dis 2014; 20: 1407-15.,LREFLobatón T et al.: J Crohns Colitis 2013, 641-51.,LREFLobatón T et al.: Inflamm Bowel Dis 2013; 19(5), 1034-42.,LREFWright et al.: Gastroenterology 2015; 148(5), 938-947.,LREFNaismith GD et al.: J Crohns Colitis 2014; 8, 1022-9.,LREFFerreiro-Iglesias R et al.: Scand J Gastroenterol 2015, 23, 1-6.,LREFFerreiro-Iglesias R1 et al. : J Clin Gastroenterol 2015; 50(2),147-51.,LREFGuardiola J. et al. Clinical Gastroenterology & Hepatology 2014; 12(11) 1865-70.,LREFLasson A et al.: United European Gastroenterol J 2015, 3(1) 72-9.,LREFBressler B et al.: Can J Gastroenterol Hepatol 2015, 29(7), 369-72.,LREFPeyrin-BL et al.: Am J Gastroenterol 2015, 110, 1324-38.,LREFRicciuto A et al.: Crit Rev Clin Lab Sci. 2019; 56(5):307-320. For laboratory use only. en 0208910332190c501 FCAL fCAL turbo en 3 FF00000005A3E00E FF00000005A3E00E 08910332190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings. en